The recent right to try legislation allows terminally ill patients to access experimental treatments, a significant move praised for prioritizing patient choice. Advocates have long fought for this freedom, which challenges the traditional FDA approval process. This initiative highlights a compassionate approach to healthcare while also raising questions about individual rights and government regulation.
